Health care stocks advanced Wednesday afternoon, with the NYSE Health Care Index rising 1% and the Health Care Select Sector SPDR Fund (XLV) up 0.7%.
The iShares Biotechnology ETF (IBB) added 0.8%.
In corporate news, Novo Nordisk's (NVO) Q1 results topped Wall Street's projections, while the Danish drugmaker tempered its 2025 sales outlook as competition from compounded obesity and diabetes drugs in the US impacted the early part of the year. Novo shares rose 1.2%.
Teva Pharmaceutical Industries (TEVA) surged nearly 9% after it posted higher Q1 non-GAAP earnings and net revenue.
Immunocore (IMCR) shares jumped 8%. The company reported Q1 net income Wednesday of $0.10 per diluted share, swinging from a loss of $0.49 a year earlier. Analysts polled by FactSet expected a loss of $0.38.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。